OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Subscribe To Our Newsletter & Stay Updated
